welcomes you to the new, improved website!The complete pathologic response rate in this study is revealed to be low, lower than expected after stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer: only 60%. The authors suggest a combined approach (SABR plus surgery), adopted in this experimental phase 2 trial, as a possible management scheme. This is questionable and further research will be needed.
You are here:
Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer
Submitted by: Marco Nardini
Source: JAMA Oncology
Keywords:
Author(s): David A. Palma, Timothy K. Nguyen, Alexander V. Louie, Richard Malthaner, Dalilah Fortin, George B. Rodrigues, Brian Yaremko, Joanna Laba, Keith Kwan, Stewart Gaede, Ting Lee, Aaron Ward, Andrew Warner, Richard Inculet
